Our purpose
To relieve suffering for people with great needs.

Overview
Neurocrine is committed to transparency in its interactions. Neurocrine commits to following the Association of British Pharmaceutical Industry (ABPI) Code of Practice which has clear requirements for transparency. Neurocrine has published details of its transfers of value required under the ABPI Code on the ABPI website and on this website. Disclosures prior to 2025 are reported under the legacy name Diurnal.